Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Nonsurgical transurethral radiofrequency collagen denaturation: results at three years after treatment.

Elser DM, Mitchell GK, Miklos JR, Nickell KG, Cline K, Winkler H, Wells WG.

Adv Urol. 2011;2011:872057. doi: 10.1155/2011/872057. Epub 2011 Dec 5.

2.

Nonsurgical transurethral collagen denaturation for stress urinary incontinence in women: 18-month results from a prospective long-term study.

Elser DM, Mitchell GK, Miklos JR, Nickell KG, Cline K, Winkler H, Wells WG.

Neurourol Urodyn. 2010 Nov;29(8):1424-8. doi: 10.1002/nau.20875.

PMID:
20976817
3.

Nonsurgical transurethral collagen denaturation for stress urinary incontinence in women: 12-month results from a prospective long-term study.

Elser DM, Mitchell GK, Miklos JR, Nickell KG, Cline K, Winkler H, Wells WG.

J Minim Invasive Gynecol. 2009 Jan-Feb;16(1):56-62. doi: 10.1016/j.jmig.2008.09.621. Epub 2008 Nov 13.

PMID:
19013110
4.

The Bacteroides fragilis transcriptome response to oxygen and H2O2: the role of OxyR and its effect on survival and virulence.

Sund CJ, Rocha ER, Tzianabos AO, Wells WG, Gee JM, Reott MA, O'Rourke DP, Smith CJ.

Mol Microbiol. 2008 Jan;67(1):129-42. Epub 2007 Nov 28. Erratum in: Mol Microbiol. 2008 Jun;68(5):1340. Tzinabos, Arthur O [corrected to Tzianabos, Arthur O].

5.

Nonsurgical, radiofrequency collagen denaturation for stress urinary incontinence: retrospective 3-year evaluation.

Appell RA, Singh G, Klimberg IW, Graham C, Juma S, Wells WG, Kanellos A, Reilley SF.

Expert Rev Med Devices. 2007 Jul;4(4):455-61.

PMID:
17605681
6.

Use of in-office anesthesia during non-surgical radiofrequency collagen denaturation for stress urinary incontinence.

Wells WG, Lenihan JP Jr.

Curr Med Res Opin. 2007 Jun;23(6):1279-84. Epub 2007 Apr 26.

PMID:
17559728
8.

Transurethral radiofrequency energy collagen micro-remodeling for the treatment of female stress urinary incontinence.

Appell RA, Juma S, Wells WG, Lenihan JP, Klimberg IW, Kanellos A, Reilley SF.

Neurourol Urodyn. 2006;25(4):331-6.

PMID:
16673379
9.

Genetic and structural analysis of the Bacteroides conjugative transposon CTn341.

Bacic M, Parker AC, Stagg J, Whitley HP, Wells WG, Jacob LA, Smith CJ.

J Bacteriol. 2005 Apr;187(8):2858-69.

11.

Perioperative mezlocillin vs cefotaxime to prevent infections after genitourinary surgery.

Childs SJ, Wells WG, Mirelman S.

Urology. 1985 Jun;25(6):657-61.

PMID:
4012967
12.

Ceftriaxone for once-a-day therapy of urinary tract infections.

Childs SJ, Wells WG, Mirelman S.

Am J Med. 1984 Oct 19;77(4C):73-6.

PMID:
6093524
13.

Ceftazidime, an open randomized comparison of 3 dosages for genitourinary infections.

Childs SJ, Wells WG, Chubb JM.

J Urol. 1983 Sep;130(3):495-7.

PMID:
6350616
14.

Antibiotic prophylaxis for genitourinary surgery in community hospitals.

Childs SJ, Wells WG, Mirelman S.

J Urol. 1983 Aug;130(2):305-8.

PMID:
6308283
15.

Perioperative use of ceftazidime as a prophylactic agent in transurethral surgery.

Childs SJ, Mirelman S, Wells WG.

J Antimicrob Chemother. 1983 Jul;12 Suppl A:71-6.

PMID:
6311789
16.

Preliminary report on a comparative trial of cefotetan and cefoxitin in the treatment of urinary tract infections.

Cox CE, Childs SJ, Wells WG, Mirelmant S, Lesky WC.

J Antimicrob Chemother. 1983 Jan;11 Suppl:227-32.

PMID:
6341350

Supplemental Content

Loading ...
Support Center